Will Chevron Acquire Hess?
Long-time Buffett favorite in the energy sector Chevron (NYSE:CVX) is…
Sell
13
BLUE Quote, Financials, Valuation and Earnings
Last price:
$3.89
Seasonality move
:
2.14%
Day range:
$3.82 - $3.99
52-week range:
$3.56 - $28.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.65x
P/B ratio:
2.05x
Volume:
148.4K
Avg. volume:
441.5K
1-year change:
-85.69%
Market cap:
$38.1M
Revenue:
$29.5M
EPS (TTM):
-$35.80
Analysts' Opinion
-
Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $23.25, bluebird bio has an estimated upside of 269.9% from its current price of $3.92.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $3.92.
Fair Value
-
According to the consensus of 5 analysts, bluebird bio has 269.9% upside to fair value with a price target of $23.25 per share.
BLUE vs. S&P 500
-
Over the past 5 trading days, bluebird bio has underperformed the S&P 500 by -2.59% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
bluebird bio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
bluebird bio revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter bluebird bio reported revenues of $10.6M.
Earnings Growth
-
bluebird bio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter bluebird bio reported earnings per share of -$6.20.
Enterprise value:
38.1M
EV / Invested capital:
--
Price / LTM sales:
0.65x
EV / EBIT:
--
EV / Revenue:
0.72x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$25.7M
Return On Assets:
-50.94%
Net Income Margin (TTM):
-551.26%
Return On Equity:
-245.94%
Return On Invested Capital:
-181.94%
Operating Margin:
-604.11%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $5.1M | $21.7M | $53.1M | $12.4M | $10.6M | |
| Gross Profit | -$8.6M | $370K | -$25.7M | $3.3M | -$1.2M | |
| Operating Income | -$442.3M | -$187.6M | -$318.5M | -$96M | -$64.1M | |
| EBITDA | -$436.2M | -$10.9M | -$216.6M | -$75.5M | -$39.7M | |
| Diluted EPS | -$122.00 | -$16.40 | -$35.80 | -$16.00 | -$6.20 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.3B | $832.3M | $160.4M | $247.1M | $150.8M | |
| Total Assets | $1.9B | $1.3B | $520.1M | $613.6M | $465.1M | |
| Current Liabilities | $196.9M | $266.6M | $126.7M | $159M | $296M | |
| Total Liabilities | $422.5M | $469.1M | $361.2M | $391.1M | $470.8M | |
| Total Equity | $1.5B | $870.5M | $158.9M | $222.5M | -$5.8M | |
| Total Debt | -- | -- | -- | -- | $70.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$436.4M | -$200.4M | -$264M | -$50.1M | -$68.9M | |
| Cash From Investing | $208.1M | $254.4M | $5.2M | $62.1M | $466K | |
| Cash From Financing | -$119.6M | $52.8M | $159.1M | -$11.8M | -$6.1M | |
| Free Cash Flow | -$446.6M | -$209.4M | -$271.3M | -$52.1M | -$69.2M | |
BLUE
Sector
Market Cap
$38.1M
$39.2M
Price % of 52-Week High
13.71%
45.99%
Dividend Yield
0%
0%
Shareholder Yield
-131.27%
-0.81%
1-Year Price Total Return
-85.69%
-38.63%
Beta (5-Year)
0.785
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$3.89
200-day SMA
Sell
Level
$11.58
Bollinger Bands (100)
Sell
Level
5.23 - 9.21
Chaikin Money Flow
Sell
Level
-259.4M
20-day SMA
Sell
Level
$3.93
Relative Strength Index (RSI14)
Sell
Level
34.31
ADX Line
Sell
Level
36.75
Williams %R
Neutral
Level
-45.8333
50-day SMA
Sell
Level
$6.09
MACD (12, 26)
Sell
Level
-0.62
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
2.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.0945)
Sell
CA Score
(Annual)
Level (-2.956)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (3.535)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.
Stock Forecast FAQ
In the current month, BLUE has received 0 Buy ratings 5 Hold ratings, and 0 Sell ratings. The BLUE average analyst price target in the past 3 months is $23.25.
-
Where Will bluebird bio Stock Be In 1 Year?
According to analysts, the consensus estimate is that bluebird bio share price will rise to $23.25 per share over the next 12 months.
-
What Do Analysts Say About bluebird bio?
Analysts are divided on their view about bluebird bio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that bluebird bio is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is bluebird bio's Price Target?
The price target for bluebird bio over the next 1-year time period is forecast to be $23.25 according to 5 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is BLUE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for bluebird bio is a Hold. 5 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of BLUE?
You can purchase shares of bluebird bio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase bluebird bio shares.
-
What Is The bluebird bio Share Price Today?
bluebird bio was last trading at $3.89 per share. This represents the most recent stock quote for bluebird bio. Yesterday, bluebird bio closed at $3.92 per share.
-
How To Buy bluebird bio Stock Online?
In order to purchase bluebird bio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Progressive Stock Go Down?
Shares of insurance giant Progressive (NYSE:PGR) have fallen considerably over…
Why Did StoneCo Stock Go Up So Much?
Brazilian fintech company StoneCo (NASDAQ:STNE) has been on a tear…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
47
RGC alert for Mar 25
Regencell Bioscience Holdings [RGC] is up 4.9% over the past day.
Buy
54
AZEK alert for Mar 25
The AZEK [AZEK] is up 1.01% over the past day.
Sell
36
MPTI alert for Mar 25
M-Tron Industries [MPTI] is up 7.48% over the past day.
